Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03856047 · ClinicalTrials.gov registry record · Phase 2
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 706
- Enrollment target
NCT03856047 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 706 participants.
The verdict
NCT03856047, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 706 participants
- Enrollment target
Study Summary
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either take NNC0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take one injection once a week or once a day, depending on the treatment. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 8 months. Participants will have 12 clinic visits with the study doctor.
Interventions
- DRUG NNC0174-0833
- DRUG Liraglutide 3.0 mg
- DRUG Placebo (NNC0174-0833)
- DRUG Placebo (Liraglutide 3.0 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03856047
The ClinicalTrials.gov registry entry for NCT03856047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NNC0174-0833 is the first listed.
NCT03856047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03856047 about?
NCT03856047 is a clinical study titled "Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.". This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and wh...
What is the current status of trial NCT03856047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 706 participants. The study started on 2019-03-01. Estimated completion is 2021-03-25.
What interventions are being tested in trial NCT03856047?
The interventions under investigation include: NNC0174-0833 (DRUG), Liraglutide 3.0 mg (DRUG), Placebo (NNC0174-0833) (DRUG), Placebo (Liraglutide 3.0 mg) (DRUG).
Who is sponsoring clinical trial NCT03856047?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.